<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="interaction" /><meta name="keywords" content="" /><title>Opioid Analgesics: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="bnf_int85-opioid-analgesics.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="bnf_int85-opioid-analgesics.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=bnf_int85-opioid-analgesics.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 07 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP8848-interactions.htm">Appendix 1 Interactions</a> &gt; <a href="PHP8852-list-of-drug-interactions.htm">List of drug interactions</a> &gt; <a href="bnf_int56-analgesics.htm">Analgesics</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="bnf_int83-tolfenamic-acid.htm" title="Previous: Tolfenamic Acid">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="bnf_int1206-tapentadol.htm" title="Next: Tapentadol">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1>Opioid Analgesics</h1><?highlighter on?><div id="pC" class="jN"><p><strong>Opioid Analgesics</strong> has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int20-alcohol.htm">Alcohol</a></td><td><p><span>enhanced hypotensive and sedative effects when </span> <span>opioid analgesics</span> <span>given with</span> <span>alcohol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int40-anaesthetics-general-intravenous.htm">Anaesthetics, General (intravenous)</a></td><td><p><span></span> <span>opioid analgesics</span> <span>possibly enhance effects of</span> <span>intravenous general anaesthetics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int46-anaesthetics-general-volatile-liquids.htm">Anaesthetics, General (volatile liquids)</a></td><td><p><span></span> <span>opioid analgesics</span> <span>possibly enhance effects of</span> <span>volatile liquid general anaesthetics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int241-antidepressants-tricyclic.htm">Antidepressants, Tricyclic</a></td><td><p><span>sedative effects possibly increased when </span> <span>opioid analgesics</span> <span>given with</span> <span>tricyclics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int311-antihistamines-sedating.htm">Antihistamines, Sedating</a></td><td class="cAI"><p><span>sedative effects possibly increased when </span> <span>opioid analgesics</span> <span>given with</span> <span>sedating antihistamines</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int363-antipsychotics.htm">Antipsychotics</a></td><td><p><span>enhanced hypotensive and sedative effects when </span> <span>opioid analgesics</span> <span>given with</span> <span>antipsychotics</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Increased risk of toxicity with myelosuppressive drugs</p></div></td></tr><tr><td><a href="bnf_int404-anxiolytics-and-hypnotics.htm">Anxiolytics and Hypnotics</a></td><td><p><span>increased sedative effect when </span> <span>opioid analgesics</span> <span>given with</span> <span>anxiolytics and hypnotics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int744-cimetidine.htm">Cimetidine</a></td><td><p><span>metabolism of </span> <span>opioid analgesics</span> <span>inhibited by</span> <span>cimetidine</span> <span>(increased plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int553-domperidone.htm">Domperidone</a></td><td><p><span></span> <span>opioid analgesics</span> <span>antagonise effects of</span> <span>domperidone</span> <span>on gastro-intestinal activity</span>  </p></td><td></td></tr><tr><td><a href="bnf_int257-maois.htm">MAOIs</a></td><td class="cAI"><p><span>possible CNS excitation or depression (hypertension or hypotension) when </span> <span>opioid analgesics</span> <span>given with</span> <span>MAOIs</span> <span>—some manufacturers advise avoid concomitant use and for 2 weeks after stopping <span>MAOIs</span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</p></div></td></tr><tr><td><a href="bnf_int613-metoclopramide.htm">Metoclopramide</a></td><td><p><span></span> <span>opioid analgesics</span> <span>antagonise effects of</span> <span>metoclopramide</span> <span>on gastro-intestinal activity</span>  </p></td><td></td></tr><tr><td><a href="bnf_int262-moclobemide.htm">Moclobemide</a></td><td class="cAI"><p><span>possible CNS excitation or depression (hypertension or hypotension) when </span> <span>opioid analgesics</span> <span>given with</span> <span>moclobemide</span> <span>—manufacturer of <span>moclobemide</span> advises consider reducing dose of <span>opioid analgesics</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int687-selegiline.htm">Selegiline</a></td><td><p><span>avoidance of </span> <span>opioid analgesics</span> <span>advised by manufacturer of</span> <span>selegiline</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Selegiline is a MAO-B inhibitor</p></div></td></tr><tr><td><a href="bnf_int1067-sodium-oxybate.htm">Sodium Oxybate</a></td><td class="cAI"><p><span></span> <span>opioid analgesics</span> <span>enhance effects of</span> <span>sodium oxybate</span> <span>(avoid concomitant use)</span>  </p></td><td></td></tr></tbody></table><p><strong>Opioid Analgesics</strong> belongs to <strong>Analgesics</strong> but <strong>Analgesics</strong> has no interactions information.</p><p><strong>Tapentadol</strong> belongs to <strong>Opioid Analgesics</strong> but has no specific interaction information.</p><p><strong>Alfentanil</strong> belongs to <strong>Opioid Analgesics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int468-diltiazem.htm">Diltiazem</a></td><td><p><span>metabolism of </span> <span>alfentanil</span> <span>inhibited by</span> <span>diltiazem</span> <span>(risk of prolonged or delayed respiratory depression)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int169-erythromycin.htm">Erythromycin</a></td><td><p><span>plasma concentration of </span> <span>alfentanil</span> <span>increased by</span> <span>erythromycin</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not apply to small amounts of erythromycin used topically</p></div></td></tr><tr><td><a href="bnf_int301-fluconazole.htm">Fluconazole</a></td><td><p><span>metabolism of </span> <span>alfentanil</span> <span>inhibited by</span> <span>fluconazole</span> <span>(risk of prolonged or delayed respiratory depression)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> In general, fluconazole interactions relate to multiple-dose treatment</p></div></td></tr><tr><td><a href="bnf_int302-itraconazole.htm">Itraconazole</a></td><td><p><span>metabolism of </span> <span>alfentanil</span> <span>possibly inhibited by</span> <span>itraconazole</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td><p><span>metabolism of </span> <span>alfentanil</span> <span>accelerated by</span> <span>rifampicin</span> <span>(reduced effect)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>alfentanil</span> <span>increased by</span> <span>ritonavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>alfentanil</span> <span>given with</span> <span>saquinavir</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int948-voriconazole.htm">Voriconazole</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>alfentanil</span> <span>increased by</span> <span>voriconazole</span> <span>(consider reducing dose of <span>alfentanil</span>)</span>  </p></td><td></td></tr></tbody></table><p><strong>Buprenorphine</strong> belongs to <strong>Opioid Analgesics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int298-ketoconazole.htm">Ketoconazole</a></td><td class="cAI"><p><span>metabolism of </span> <span>buprenorphine</span> <span>inhibited by</span> <span>ketoconazole</span> <span>(reduce dose of <span>buprenorphine</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td><p><span>plasma concentration of </span> <span>buprenorphine</span> <span>possibly increased by</span> <span>ritonavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1055-tipranavir.htm">Tipranavir</a></td><td><p><span></span> <span>buprenorphine</span> <span>possibly reduces plasma concentration of</span> <span>tipranavir</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Codeine</strong> belongs to <strong>Opioid Analgesics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int342-antimuscarinics.htm">Antimuscarinics</a></td><td><p><span>possible increased risk of antimuscarinic side-effects when </span> <span>codeine</span> <span>given with</span> <span>antimuscarinics</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Many drugs have antimuscarinic effects; concomitant use of two or more such drugs can increase side-effects such as dry mouth, urine retention, and constipation; concomitant use can also lead to confusion in the elderly. Interactions do not generally apply to antimuscarinics used by inhalation</p></div></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td><p><span>metabolism of </span> <span>codeine</span> <span>accelerated by</span> <span>rifampicin</span> <span>(reduced effect)</span>  </p></td><td></td></tr></tbody></table><p><strong>Dextromethorphan</strong> belongs to <strong>Opioid Analgesics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int942-memantine.htm">Memantine</a></td><td class="cAI"><p><span>increased risk of CNS toxicity when </span> <span>dextromethorphan</span> <span>given with</span> <span>memantine</span> <span>(manufacturer of <span>memantine</span> advises avoid concomitant use)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int262-moclobemide.htm">Moclobemide</a></td><td class="cAI"><p><span>possible CNS excitation or depression (hypertension or hypotension) when </span> <span>dextromethorphan</span> <span>given with</span> <span>moclobemide</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1051-rasagiline.htm">Rasagiline</a></td><td class="cAI"><p><span>avoid concomitant use of </span> <span>dextromethorphan</span> <span>with</span> <span>rasagiline</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Rasagiline is a MAO-B inhibitor</p></div></td></tr></tbody></table><p><strong>Dextropropoxyphene</strong> belongs to <strong>Opioid Analgesics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td class="cAI"><p><span></span> <span>dextropropoxyphene</span> <span>enhances effects of</span> <span>carbamazepine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>dextropropoxyphene</span> <span>increased by</span> <span>ritonavir</span> <span>(risk of toxicity)—avoid concomitant use</span>  </p></td><td></td></tr></tbody></table><p><strong>Diamorphine</strong> belongs to <strong>Opioid Analgesics</strong> but has no specific interaction information.</p><p><strong>Dihydrocodeine</strong> belongs to <strong>Opioid Analgesics</strong> but has no specific interaction information.</p><p><strong>Diphenoxylate</strong> belongs to <strong>Opioid Analgesics</strong> but has no specific interaction information.</p><p><strong>Dipipanone</strong> belongs to <strong>Opioid Analgesics</strong> but has no specific interaction information.</p><p><strong>Fentanyl</strong> belongs to <strong>Opioid Analgesics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int300-antifungals-triazole.htm">Antifungals, Triazole</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>fentanyl</span> <span>possibly increased by</span> <span>triazoles</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int617-baclofen.htm">Baclofen</a></td><td><p><span>increased sedative effect when </span> <span>fentanyl</span> <span>given with</span> <span>baclofen</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int43-etomidate.htm">Etomidate</a></td><td><p><span></span> <span>fentanyl</span> <span>inhibits metabolism of</span> <span>etomidate</span> <span>(consider reducing dose of <span>etomidate</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int421-midazolam.htm">Midazolam</a></td><td><p><span></span> <span>fentanyl</span> <span>possibly inhibits metabolism of</span> <span>midazolam</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td><p><span>metabolism of </span> <span>fentanyl</span> <span>accelerated by</span> <span>rifampicin</span> <span>(reduced effect)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>fentanyl</span> <span>increased by</span> <span>ritonavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>fentanyl</span> <span>given with</span> <span>saquinavir</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr></tbody></table><p><strong>Hydromorphone</strong> belongs to <strong>Opioid Analgesics</strong> but has no specific interaction information.</p><p><strong>Meptazinol</strong> belongs to <strong>Opioid Analgesics</strong> but has no specific interaction information.</p><p><strong>Methadone</strong> belongs to <strong>Opioid Analgesics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int907-abacavir.htm">Abacavir</a></td><td><p><span>plasma concentration of </span> <span>methadone</span> <span>possibly reduced by</span> <span>abacavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int809-amisulpride.htm">Amisulpride</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>methadone</span> <span>given with</span> <span>amisulpride</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int363-antipsychotics.htm">Antipsychotics</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>methadone</span> <span>given with</span> <span>antipsychotics</span> <span>that prolong the QT interval</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Increased risk of toxicity with myelosuppressive drugs</p></div></td></tr><tr><td><a href="bnf_int1009-atomoxetine.htm">Atomoxetine</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>methadone</span> <span>given with</span> <span>atomoxetine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td><p><span>plasma concentration of </span> <span>methadone</span> <span>reduced by</span> <span>carbamazepine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int397-didanosine.htm">Didanosine</a></td><td><p><span></span> <span>methadone</span> <span>possibly reduces plasma concentration of</span> <span>didanosine</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Antacids in tablet formulation may affect absorption of other drugs</p></div></td></tr><tr><td><a href="bnf_int874-efavirenz.htm">Efavirenz</a></td><td><p><span>plasma concentration of </span> <span>methadone</span> <span>reduced by</span> <span>efavirenz</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int301-fluconazole.htm">Fluconazole</a></td><td><p><span>plasma concentration of </span> <span>methadone</span> <span>increased by</span> <span>fluconazole</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> In general, fluconazole interactions relate to multiple-dose treatment</p></div></td></tr><tr><td><a href="bnf_int234-fluoxetine.htm">Fluoxetine</a></td><td><p><span>plasma concentration of </span> <span>methadone</span> <span>possibly increased by</span> <span>fluoxetine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int235-fluvoxamine.htm">Fluvoxamine</a></td><td><p><span>plasma concentration of </span> <span>methadone</span> <span>possibly increased by</span> <span>fluvoxamine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1019-fosamprenavir.htm">Fosamprenavir</a></td><td><p><span>plasma concentration of </span> <span>methadone</span> <span>reduced by</span> <span>fosamprenavir</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Fosamprenavir is a prodrug of amprenavir</p></div></td></tr><tr><td><a href="bnf_int842-nelfinavir.htm">Nelfinavir</a></td><td><p><span>plasma concentration of </span> <span>methadone</span> <span>reduced by</span> <span>nelfinavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int843-nevirapine.htm">Nevirapine</a></td><td><p><span>plasma concentration of </span> <span>methadone</span> <span>possibly reduced by</span> <span>nevirapine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int236-paroxetine.htm">Paroxetine</a></td><td><p><span>plasma concentration of </span> <span>methadone</span> <span>possibly increased by</span> <span>paroxetine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int437-phenobarbital.htm">Phenobarbital</a></td><td><p><span>plasma concentration of </span> <span>methadone</span> <span>reduced by</span> <span>phenobarbital</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td><p><span>metabolism of </span> <span>methadone</span> <span>accelerated by</span> <span>phenytoin</span> <span>(reduced effect and risk of withdrawal effects)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td><p><span>metabolism of </span> <span>methadone</span> <span>accelerated by</span> <span>rifampicin</span> <span>(reduced effect)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1225-rilpivirine.htm">Rilpivirine</a></td><td><p><span>plasma concentration of </span> <span>methadone</span> <span>possibly reduced by</span> <span>rilpivirine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td><p><span>plasma concentration of </span> <span>methadone</span> <span>reduced by</span> <span>ritonavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>methadone</span> <span>given with</span> <span>saquinavir</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int237-sertraline.htm">Sertraline</a></td><td><p><span>plasma concentration of </span> <span>methadone</span> <span>possibly increased by</span> <span>sertraline</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int905-st-johns-wort.htm">St John's Wort</a></td><td><p><span>plasma concentration of </span> <span>methadone</span> <span>possibly reduced by</span> <span>St John's wort</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1216-telaprevir.htm">Telaprevir</a></td><td class="cAI"><p><span>caution with </span> <span>methadone</span> <span>advised by manufacturer of</span> <span>telaprevir</span> <span>(risk of ventricular arrhythmias)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1227-vandetanib.htm">Vandetanib</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span> <span>methadone</span> <span>given with</span> <span>vandetanib</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int948-voriconazole.htm">Voriconazole</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>methadone</span> <span>increased by</span> <span>voriconazole</span> <span>(consider reducing dose of <span>methadone</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int403-zidovudine.htm">Zidovudine</a></td><td><p><span></span> <span>methadone</span> <span>possibly increases plasma concentration of</span> <span>zidovudine</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Increased risk of toxicity with nephrotoxic and myelosuppressive drugs—for further details consult product literature</p></div></td></tr></tbody></table><p><strong>Morphine</strong> belongs to <strong>Opioid Analgesics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int617-baclofen.htm">Baclofen</a></td><td><p><span>increased sedative effect when </span> <span>morphine</span> <span>given with</span> <span>baclofen</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int447-esmolol.htm">Esmolol</a></td><td><p><span></span> <span>morphine</span> <span>possibly increases plasma concentration of</span> <span>esmolol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int282-gabapentin.htm">Gabapentin</a></td><td><p><span></span> <span>morphine</span> <span>increases bioavailability of</span> <span>gabapentin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td><p><span>metabolism of </span> <span>morphine</span> <span>accelerated by</span> <span>rifampicin</span> <span>(reduced effect)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td><p><span>plasma concentration of </span> <span>morphine</span> <span>possibly reduced by</span> <span>ritonavir</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Oxycodone</strong> belongs to <strong>Opioid Analgesics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td><p><span>metabolism of </span> <span>oxycodone</span> <span>possibly accelerated by</span> <span>rifampicin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int946-telithromycin.htm">Telithromycin</a></td><td><p><span>metabolism of </span> <span>oxycodone</span> <span>inhibited by</span> <span>telithromycin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int948-voriconazole.htm">Voriconazole</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>oxycodone</span> <span>increased by</span> <span>voriconazole</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Papaveretum</strong> belongs to <strong>Opioid Analgesics</strong> but has no specific interaction information.</p><p><strong>Pentazocine</strong> belongs to <strong>Opioid Analgesics</strong> but has no specific interaction information.</p><p><strong>Pethidine</strong> belongs to <strong>Opioid Analgesics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1024-duloxetine.htm">Duloxetine</a></td><td><p><span>possible increased serotonergic effects when </span> <span>pethidine</span> <span>given with</span> <span>duloxetine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int257-maois.htm">MAOIs</a></td><td class="cAI"><p><span>CNS excitation or depression (hypertension or hypotension) when </span> <span>pethidine</span> <span>given with</span> <span>MAOIs</span> <span>—avoid concomitant use and for 2 weeks after stopping <span>MAOIs</span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</p></div></td></tr><tr><td><a href="bnf_int262-moclobemide.htm">Moclobemide</a></td><td class="cAI"><p><span>possible CNS excitation or depression (hypertension or hypotension) when </span> <span>pethidine</span> <span>given with</span> <span>moclobemide</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1051-rasagiline.htm">Rasagiline</a></td><td class="cAI"><p><span>risk of CNS toxicity when </span> <span>pethidine</span> <span>given with</span> <span>rasagiline</span> <span>(avoid <span>pethidine</span> for 2 weeks after <span>rasagiline</span>)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Rasagiline is a MAO-B inhibitor</p></div></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>pethidine</span> <span>reduced by</span> <span>ritonavir</span> <span>, but plasma concentration of toxic <span>pethidine</span> metabolite increased (avoid concomitant use)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int687-selegiline.htm">Selegiline</a></td><td class="cAI"><p><span>hyperpyrexia and CNS toxicity reported when </span> <span>pethidine</span> <span>given with</span> <span>selegiline</span> <span>(avoid concomitant use)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Selegiline is a MAO-B inhibitor</p></div></td></tr></tbody></table><p><strong>Remifentanil</strong> belongs to <strong>Opioid Analgesics</strong> but has no specific interaction information.</p><p><strong>Tramadol</strong> belongs to <strong>Opioid Analgesics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int232-antidepressants-ssri.htm">Antidepressants, SSRI</a></td><td class="cAI"><p><span>increased risk of CNS toxicity when </span> <span>tramadol</span> <span>given with</span> <span>SSRIs</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int241-antidepressants-tricyclic.htm">Antidepressants, Tricyclic</a></td><td class="cAI"><p><span>increased risk of CNS toxicity when </span> <span>tramadol</span> <span>given with</span> <span>tricyclics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int363-antipsychotics.htm">Antipsychotics</a></td><td><p><span>increased risk of convulsions when </span> <span>tramadol</span> <span>given with</span> <span>antipsychotics</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Increased risk of toxicity with myelosuppressive drugs</p></div></td></tr><tr><td><a href="bnf_int1009-atomoxetine.htm">Atomoxetine</a></td><td><p><span>possible increased risk of convulsions when </span> <span>tramadol</span> <span>given with</span> <span>atomoxetine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td><p><span>effects of </span> <span>tramadol</span> <span>reduced by</span> <span>carbamazepine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td class="cAI"><p><span></span> <span>tramadol</span> <span>enhances anticoagulant effect of</span> <span>coumarins</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int1024-duloxetine.htm">Duloxetine</a></td><td><p><span>possible increased serotonergic effects when </span> <span>tramadol</span> <span>given with</span> <span>duloxetine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int257-maois.htm">MAOIs</a></td><td class="cAI"><p><span>possible increased serotonergic effects and increased risk of convulsions when </span> <span>tramadol</span> <span>given with</span> <span>MAOIs</span> <span>—some manufacturers advise avoid concomitant use and for 2 weeks after stopping <span>MAOIs</span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</p></div></td></tr><tr><td><a href="bnf_int823-mirtazapine.htm">Mirtazapine</a></td><td><p><span>possible increased serotonergic effects when </span> <span>tramadol</span> <span>given with</span> <span>mirtazapine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1045-ondansetron.htm">Ondansetron</a></td><td><p><span>effects of </span> <span>tramadol</span> <span>possibly antagonised by</span> <span>ondansetron</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int240-venlafaxine.htm">Venlafaxine</a></td><td><p><span>possible increased serotonergic effects when </span> <span>tramadol</span> <span>given with</span> <span>venlafaxine</span> <span></span>  </p></td><td></td></tr></tbody></table></div><div id="pS"><p>Sub-sections</p><ul class="jT"><li><a href="bnf_int1206-tapentadol.htm" title="Tapentadol">Tapentadol</a></li><li><a href="bnf_int86-alfentanil.htm" title="Alfentanil">Alfentanil</a></li><li><a href="bnf_int87-buprenorphine.htm" title="Buprenorphine">Buprenorphine</a></li><li><a href="bnf_int88-codeine.htm" title="Codeine">Codeine</a></li><li><a href="bnf_int882-dextromethorphan.htm" title="Dextromethorphan">Dextromethorphan</a></li><li><a href="bnf_int90-dextropropoxyphene.htm" title="Dextropropoxyphene">Dextropropoxyphene</a></li><li><a href="bnf_int91-diamorphine.htm" title="Diamorphine">Diamorphine</a></li><li><a href="bnf_int92-dihydrocodeine.htm" title="Dihydrocodeine">Dihydrocodeine</a></li><li><a href="bnf_int93-diphenoxylate.htm" title="Diphenoxylate">Diphenoxylate</a></li><li><a href="bnf_int94-dipipanone.htm" title="Dipipanone">Dipipanone</a></li><li><a href="bnf_int95-fentanyl.htm" title="Fentanyl">Fentanyl</a></li><li><a href="bnf_int835-hydromorphone.htm" title="Hydromorphone">Hydromorphone</a></li><li><a href="bnf_int96-meptazinol.htm" title="Meptazinol">Meptazinol</a></li><li><a href="bnf_int97-methadone.htm" title="Methadone">Methadone</a></li><li><a href="bnf_int98-morphine.htm" title="Morphine">Morphine</a></li><li><a href="bnf_int901-oxycodone.htm" title="Oxycodone">Oxycodone</a></li><li><a href="bnf_int100-papaveretum.htm" title="Papaveretum">Papaveretum</a></li><li><a href="bnf_int101-pentazocine.htm" title="Pentazocine">Pentazocine</a></li><li><a href="bnf_int102-pethidine.htm" title="Pethidine">Pethidine</a></li><li><a href="bnf_int105-remifentanil.htm" title="Remifentanil">Remifentanil</a></li><li><a href="bnf_int106-tramadol.htm" title="Tramadol">Tramadol</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="bnf_int83-tolfenamic-acid.htm">Previous: Tolfenamic Acid</a> | <a class="top" href="bnf_int85-opioid-analgesics.htm#">Top</a> | <a accesskey="]" href="bnf_int1206-tapentadol.htm">Next: Tapentadol</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>